Vanderbilt registers Phase 2 toripalimab trial in esophageal cancer, backed by Coherus
A new Vanderbilt-Ingram Cancer Center trial will test Coherus's toripalimab before and after chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
A newly registered trial record details a Phase 2 study combining Coherus Oncology's toripalimab with chemoradiotherapy in esophageal cancer.
- Vanderbilt-Ingram Cancer Center is the lead sponsor of a Phase 2 trial (NCT07836049) testing induction toripalimab followed by definitive chemoradiotherapy and up to one year of adjuvant toripalimab in patients with stage II-IVA esophageal squamous cell carcinoma, with Coherus Oncology, Inc. listed as a collaborator. The study is not yet recruiting, with an estimated start date of 2026-12-31 and primary completion estimated for 2030-12-31.1 Planned enrollment is 20 participants.1 The primary outcome is the clinical complete response rate measured 4-12 weeks after completion of standard-of-care definitive chemoradiotherapy.1 The record notes that toripalimab will be provided to the study by Coherus.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.